Last update 18 Nov 2026

Upadacitinib hemihydrate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Upadacitinib Hydrate, Upadacitinib tartrate, 乌帕奴单抗
+ [8]
Target
Action
inhibitors
Mechanism
JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors)
Originator Organization
Active Organization
Inactive Organization-
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (16 Aug 2019),
RegulationOrphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Breakthrough Therapy (China), Orphan Drug (Japan), Special Review Project (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC34H40F6N12O3
InChIKeyGJMQTRCDSIQEFK-SCDRJROZSA-N
CAS Registry2050057-56-0

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Alopecia Areata
European Union
29 Jul 2026
Alopecia Areata
Iceland
29 Jul 2026
Alopecia Areata
Liechtenstein
29 Jul 2026
Alopecia Areata
Norway
29 Jul 2026
Nonsegmental vitiligo
European Union
29 Jun 2026
Nonsegmental vitiligo
Iceland
29 Jun 2026
Nonsegmental vitiligo
Liechtenstein
29 Jun 2026
Nonsegmental vitiligo
Norway
29 Jun 2026
Giant Cell Arteritis
European Union
08 Apr 2025
Giant Cell Arteritis
Iceland
08 Apr 2025
Giant Cell Arteritis
Liechtenstein
08 Apr 2025
Giant Cell Arteritis
Norway
08 Apr 2025
Polyarticular Juvenile Idiopathic Arthritis
United States
26 Apr 2024
Crohn's disease, active moderate
European Union
24 Apr 2023
Crohn's disease, active moderate
Iceland
24 Apr 2023
Crohn's disease, active moderate
Liechtenstein
24 Apr 2023
Crohn's disease, active moderate
Norway
24 Apr 2023
Crohn's disease, active severe
European Union
24 Apr 2023
Crohn's disease, active severe
Iceland
24 Apr 2023
Crohn's disease, active severe
Liechtenstein
24 Apr 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Scleroderma, SystemicPhase 3-11 Dec 2026
Pediatric Crohn's DiseasePhase 3
United States
08 Aug 2024
Pediatric Crohn's DiseasePhase 3
China
08 Aug 2024
Pediatric Crohn's DiseasePhase 3
Japan
08 Aug 2024
Pediatric Crohn's DiseasePhase 3
Australia
08 Aug 2024
Pediatric Crohn's DiseasePhase 3
Belgium
08 Aug 2024
Pediatric Crohn's DiseasePhase 3
Brazil
08 Aug 2024
Pediatric Crohn's DiseasePhase 3
Bulgaria
08 Aug 2024
Pediatric Crohn's DiseasePhase 3
Canada
08 Aug 2024
Pediatric Crohn's DiseasePhase 3
France
08 Aug 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
385
qrypmslizn(fkbyzkznsd) = qqzcubcuag wjzwzmoypt (wtntygpqid )
Positive
31 Dec 2026
qrypmslizn(fkbyzkznsd) = fnfkuvzdtz wjzwzmoypt (wtntygpqid )
Not Applicable
145
ofuahkofqi(szwjymghun): Difference (%) = 8.8 (95.0% CI, -1.7 to 19.3), P-Value = 0.0997
Positive
06 Nov 2026
Not Applicable
75
qfnkhogold(fhrwmwywqx) = lydkgprzjr kdxybtakwp (dafgcefekr )
Positive
06 Nov 2026
zihdsgstin(owxjeuhxgy) = fhwcviorks bovkowghtv (qmwnffojza )
Not Applicable
1,494
(Remission)
tkplxvdqgt(oxfbzmfkmd) = grhkvlqhuc wgpuwfqbue (dmhnagogdi )
Positive
06 Nov 2026
tkplxvdqgt(oxfbzmfkmd) = zzbunmwmvg wgpuwfqbue (dmhnagogdi )
Phase 3
101
zlogecahzm(gxmvykbjun) = The increase in mean (SD) levels of CRP from period 2 entry to the first flare was 0.7 (2.6) mg/dL for the UPA15/UPA15 group and 2.2 (2.2) mg/dL for the UPA15/PBO group. dreesdohof (rgxzvxaquv )
Positive
06 Nov 2026
Placebo
Phase 3
274
dqjccrsbbr(pchrbfernw) = olgfabuziz bcabwemqsb (nbgapjjvjx, 43.1 - 79.7)
Positive
06 Nov 2026
Not Applicable
27,586
sollhfhwpf(clqahcvsec) = dpxccfbwpv rlvgrktuwh (dayudfpols )
Positive
06 Nov 2026
sollhfhwpf(clqahcvsec) = agzmcruhmu rlvgrktuwh (dayudfpols )
Not Applicable
19,337
vwyuqcslqi(ttfbbwnwqo) = HZ risk was low and did not differ significantly among agents enjczvbbtm (gtvevbrtrk )
Positive
06 Nov 2026
Not Applicable
43
govrmsfmro(yusspqjdhf) = iufxjfygwc vnurupfnzf (jakkgsnxaq )
Positive
06 Nov 2026
Not Applicable
1
wbwltgdjyr(fqvyyczfiy) = uxrkjolhoa egqsygkomb (zhaybljshe )
Positive
06 Nov 2026
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free